BIOLIFE SOLUTIONS INC. overview

BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair PR Newswire BOTHELL, Wash., March 18, 2025 BOTHELL, Wash. , March 18, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit...

BioLife Solutions Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire BOTHELL, Wash., March 3, 2025 Cell Processing revenue up 7% sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12% over prior year to $73.5 million GAAP gross margin of 60% and non-GAAP adjusted gross margin of 63% for the fourth quarter GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million , or 18% of total revenue for the...

BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025 PR Newswire BOTHELL, Wash., Feb. 20, 2025 BOTHELL, Wash. , Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. The Company will...

BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2024 Unaudited Revenue from Continuing Operations PR Newswire BOTHELL, Wash., Jan. 13, 2025 Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million Unaudited revenue for FY2024 from Cell Processing of $73.5 million , exceeded the high end of previously raised guidance BOTHELL, Wash. , Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer...

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors PR Newswire BOTHELL, Wash., Dec. 16, 2024 BOTHELL, Wash. , Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt , Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a recognized leader in bioprocessing innovation, to its...

BioLife Solutions Announces $6.1 million Sale of its Custom Biogenic Systems Freezer Subsidiary PR Newswire BOTHELL, Wash., Nov. 14, 2024 Completes the Company's strategic move away from capital equipment businesses BOTHELL, Wash. , Nov. 14, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer...

BioLife Solutions Reports Third Quarter 2024 Financial Results PR Newswire BOTHELL, Wash., Nov. 12, 2024 Cell Processing revenue grew 6% sequentially to $19.0 million ; 43% increase compared to 2023 GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20% Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million ; total 2024 revenue guidance of $98.0...

BioLife Solutions Announces $73 Million Sale of its SciSafe Biostorage Subsidiary PR Newswire BOTHELL, Wash., Nov. 12, 2024 Strategic divestiture heightens focus on proprietary, higher-margin cell processing products All-cash transaction fortifies balance sheet BOTHELL, Wash. , Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market,...